pomalidomide will be self-administered as a single dose orally
Sponsors
Johnson and Johnson Private Limited, Yamazaki Hiroshi, Nakama Takahiro
Conditions
Health Condition 1: C900- Multiple myelomaMultiple MyelomaRelapsed or Refractory Multiple Myeloma
Phase 3
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination with Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Active, not recruitingJPRN-jRCT2051220102
Start: 2022-12-06Target: 810Updated: 2026-06-29
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants with Relapsed or Refractory Myeloma who Have Received an Anti-CD38 Antibody and Lenalidomide
RecruitingCTRI/2024/02/063266
Target: 795Updated: 2024-04-29
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Active, not recruitingJPRN-jRCT2031240026
Start: 2024-05-08Target: 795Updated: 2026-06-29